143. Carvalho K, Martin E, Ces A, Sarrazin N, Lagouge-Roussey P, Nous C, Boucherit L, Youssef I, Prigent A, Faivre E, Eddarkaoui S, Gauvrit T, Vieau D, Boluda S, Huin V, Fontaine B, Buée L, Delatour B, Dutar P, Sennlaub F, Guillonneau X, Blum D*, Delarasse C* (2021) P2X7-deficiency improves plasticity and cognitive abilities in a mouse model of Tauopathy. Prog Neurobiol. 206:102139. DB corresponding author
142. Brigas HC, Ribeiro M, Coelho JE, Gomes R, Gomez-Murcia V, Carvalho K, Faivre E, Costa-Pereira S, Darrigues J, de Almeida AA, Buée L, Dunot J, Marie H, Pousinha PA, Blum D, Silva-Santos B, Lopes LV, Ribot JC (2021) IL-17 triggers the onset of cognitive and synaptic deficits in early stages of Alzheimer's disease. Cell Reports 236(9):109574.
141. Chang CP, Chang YG, Chuang PY, Nguyen TNA, Chou FY, Cheng SJ, Chen HM, Jin LW, Carvalho K, Huin V, Buée L, Liao YF, Lin CJ, Blum D, Yijuang Chern (2021) Equilibrative nucleoside transporter 1 inhibition rescues energy dysfunction and pathology in a model of tauopathy. Acta Neuropathologica Communications (in press). DB corresponding author
140. Nebie O, Carvalho K, Barro L, Delila L, Faivre E, Renn TY, Chou ML, Wu YW, Niem-Redene A, Chou SY, Buée L, Hu CJ, Peng CW, Devos D, Blum D*, Burnouf T* (2021) Human platelet lysate biotherapy for traumatic brain injury: preclinical assessment. Brain. awab205. doi: 10.1093/brain/awab205. DB corresponding author
139. Tautou M, Eddarkaoui S, Descamps F, Larchanché PE, Dumoulin M, Lamarre C, Blum D, Buée L, P. Melnyk, N. Sergeant (2021) A β-secretase modulator decreases Tau pathology and preserves short-term memory in a mouse model of neurofibrillary degeneration. Frontiers in Pharmacology (in press).
138. Vautheny A, Duwat C, Aurégan G, Joséphine C, Hérard AS, Jan C, Mitja J, Gipchtein P, Gaillard MC, Buée L, Blum D, Hantraye P, Bonvento G, Brouillet E, Cambon K, Bemelmans AP (2021) THY-Tau22 mouse model accumulates more tauopathy at late stage of the disease in response to microglia deactivation through TREM2 deficiency. Neurobiol Dis. 155:105398.
137. Pietrowski MJ, Gabr AA, Kozlov S, Blum D, Halle A, Carvalho K (2021) Glial Purinergic Signaling in Neurodegeneration. Front Neurol. 12:654850.
136. Maté de Gérando A, d'Orange M, Augustin E, Joséphine C, Aurégan G, Gaudin-Guérif M, Guillermier M, Hérard AS, Stimmer L, Petit F, Gipchtein P, Jan C, Escartin C, Selingue E, Carvalho K, Blum D, Brouillet E, Hantraye P, Gaillard MC, Bonvento G, Bemelmans AP, Cambon K (2021- Neuronal tau species transfer to astrocytes and induce their loss according to tau aggregation state. Brain. 144(4):1167-1182.
135. Hartnell I, Blum D, Nicoll JAR, Dorothee G, Boche D (2020) Glial cells and adaptive immunity in frontotemporal dementia with tau pathology. Brain 144(3):724-745.
134. Nebie O, Barro L, Wu YW, Knutson F, Buée L, Devos D, Pong CW, Blum D* and Burnouf T* Heat-treated human platelet pellet lysate modulates microglia activation, favors wound healing and promotes neuronal differentiation in vitro (2020) Platelets 2020 Feb 27:1-12. doi: 10.1080/09537104.2020.1732324.
133. Degiorgis L, Karatas M, Sourty M, Faivre E, Lamy J, Noblet V, Bienert T, Reisert M, von Elverfeldt D, Buée L, Blum D , Boutillier AL , Armspach JP , Blanc F and Harsan LA (2020) Brain networks remodeling reflects Tau-related pathology prior to memory deficits in Thy-Tau22 mice. Brain (in press)
132. Sierksma A, Lu A, Salta E, Mancuso R, Zoco J, Blum D, Buee , Fiers M, De Strooper B (2020) Novel Alzheimer risk genes determine the microglia response to amyloid-beta but not to TAU pathology. EMBO Mol Med doi: 10.15252/emmm.201910606.
131. Gomez-Murcia V, Sandau U, Ferry B, Parrot S, Laurent C, Basquin M, Buée L, Boison D & Blum D. (2020) Hyperexcitability and seizures in the THY-Tau22 mouse model of tauopathy. Neurobiol Aging. 2020 Oct;94:265-270. doi: 10.1016/j.neurobiolaging.2020.06.004.
130. Duriez P, Eddarkaoui S, Blum D, Dickson SL, Gorwood P, Tolle V, Viltart O.(2020- Does physical activity associated with chronic food restriction alleviate anxiety like behaviour, in female mice? Horm Behav. 2020 Jul 9;124:104807.
129. Ahmed T, Van Der Jeugd A, Caillierez R, Buee L, Blum D, D'Hooge R, Balschun D (2020) Chronic sodium selenate treatment restores deficits in cognition and synaptic plasticity in a murine model of tauopathy. Frontiers in Molecular Neuroscience 13:570223.
128. Ising C, Venegas C, Zhang S, Scheiblich H, Schmidt S, Saecker A, Schwartz S, Albasset S, McManus R, Tejera D, Griep A, Santarelli F, Brosseron F, Opitz S, Stunden J, Merten M, Kayed R, Golenbock D, Blum D, Latz E, Buee L & Heneka MT (2019) Innate immune activation of the NLRP3 inflammasome pathway drives tau pathology. Nature 575 (7784), 669-673.
127. Faldini E, Ahmed T, Buée L, Blum D & Balschun D (2019) Tau- but not Aß -pathology enhances NMDAR-dependent depotentiation in AD-mouse models. Acta Neuropathologica Communications 7(1):202.
126. Gratuze M, Joly-Amado A, Buee L, Vieau D, Blum D (2019) Tau, diabetes and insulin. Adv Exp Med Biol. 2019;1184:259-287. doi: 10.1007/978-981-32-9358-8_21.
125. Fernandez-Gomez F, Tran H, Dhaenens CM, Caillet-Boudin ML, Schraen-Maschke S, Blum D, Sablonnière B, Buée-Scherrer V, Buee L, Sergeant N. Myotonic Dystrophy: an RNA Toxic Gain of Function Tauopathy? Adv Exp Med Biol. 2019;1184:207-216. doi: 10.1007/978-981-32-9358-8_17.
124. Nebie O, Devos D, Vingtdeux V, Barro L, Devedjian JC, Jonneaux A, Chou ML, Bordet R, Buée L, Knutson F, Blum D* & Burnouf T* (2019) The neuroprotective activity of heat-treated human platelet lysate biomaterials manufactured from outdated pathogen-reduced (amotosalen/UVA) platelet concentrates. Journal of Biomedical Science 26(1):89.
123. Zappettini S, Faivre E, Ghestem A, Carrier S, Buée L, Blum D, Esclapez M & Bernard C (2019) Caffeine consumption during pregnancy accelerates 1 the development of ognitive deficits in offspring in a model of tauopathy. Frontiers in Cellular Neuroscience 13:438.
122. Carvalho K, Faivre E, Pietrowski MJ, Marques X, Gomez-Murcia V, Deleau A, Huin V, Hansen JN, Kozlov S, Danis C, Temido-Ferreira M, Coelho JE, Mériaux C, Eddarkaoui S, Le Gras S, Dumoulin M, Cellai L, NeuroCEB Brain Bank, Landrieu I, Chern Y, Hamdane M, Buée L, Boutillier AL, Levi S, Halle A, Lopes LV & Blum D. Exacerbation of C1q dysregulation, synaptic loss and memory deficits in Tau pathology linked to neuronal adenosine A2A receptors. Brain 142(11):3636-3654.
121. Paiva I*, Carvalho K*, Cellai L*, Santos P, Pavlou MAS, Jain G, Gnad T, Pfeifer A, Vieau D, Fisher A, Buée L, Outeiro TF* & Blum D* (2019) A2AR-induced transcriptional deregulation in astrocytes: an in vitro study ; Glia doi: 10.1002/glia.23688
120. Sergeant N, Vingt-deux V, Gay M, Eddarkaoui S, Le Fur N, Laurent C, Caillierez R, Obriot H, Larchanché PE, Farce A, Carato P, Dallemagne P, Buee-Scherrer V, Blum D, Hamdane M, Buée L & Melnyk P (2017) Novel piperazine drugs prevent neurofibrillary degeneration and amyloid deposition, and improve memory in animal models of Alzheimer's disease. Neurobiology of Disease 129:217-233.
119. Leboucher A, Ahmed T, Caron E, Tailleux A, Raison S, Joly-Amado A, Marciniak E, Carvalho K, Hamdane M, Bantubungi K, Lancel S, Eddarkaoui S, Caillierez R, Vallez E, Staels B, Vieau D, Balschun D, Buee L & Blum D (2019) Brain insulin response and peripheral metabolic changes in a Tau transgenic mouse model. Neurobiology of Disease 125:14-22.
118. Sierksma A, Lu A, Salta E, Mancuso R, Zoco J, Blum D, Buee , Fiers M, De Strooper B (2019) Novel Alzheimer risk genes determine the microglia response to amyloid-<beta> but not to TAU pathology BioRxiv. https://doi.org/10.1101/491902
117. Joly-Amado A, Gratuze M, Benderradji H, Vieau D, Buée L & Blum D. Brain insulin signaling and Tau: impact for Alzheimer’s disease and Tauopathies ? Med Sci (in press)
116. Chatterjee S, Schneider-Anthony A, Cassel R, Merienne K, Cosquer B, Sinha S, Kumar M, Chaturderby P, Eswaramoorthy M, Le Gras S, Keime C, Dutar P, Petsophonsakul P, Rampon C, Cassel JC, Buée L, Blum D, Kundu TK & Boutillier AL (2018) Reinstating plasticity and memory in a tauopathy mouse model with an acetyltransferase activator. EMBO Mol Med (in press). pii: e8587. doi: 10.15252/emmm.201708587.
115. Sierksma A, Lu A, Salta E, Vanden Eynden E, Callaerts-Vegh Z, D’Hooge R, Blum D, Buée L, Fiers M & De Strooper B (2018) Deregulation of neuronal miRNAs induced by Aβ or TAU pathology. Mol Neurodegeneration 13(1):54. doi: 10.1186/s13024-018-0285-1.
114. Cellai L*, Carvalho K*, Faivre E, Deleau A, Vieau D, Buee, Blum D, Mériaux C, Gomez Murcia V (2018) The adenosinergic signaling: a complex but promising therapeutic target for Alzheimer's disease. Frontiers in Neuroscience 12:520. doi: 10.3389/fnins.2018.00520. DB corresponding author
113. Faivre E, Coelho JE, Zornbach K, Malik E, Baqi Y, Schneider M, Cellai L, Carvalho K, Sebda S, Figeac M, Eddarkaoui S, Caillierez R, Chern Y, Heneka M, Sergeant N, Müller CE, Halle A, Buée L, Lopes LV & Blum D. Beneficial effect of a selective adenosine A2A receptor antagonist in the APPswe/PS1dE9 mouse model of Alzheimer’s Disease. Frontiers in Molecular Neuroscience 11:235.
112. Temido-Ferreira M, Ferreira DG, Batalha VL, Marques-Morgado I, Coelho JE, Pereira P, Gomes R, Carvalho S, Canas PM, Cuvelier L, Buée-Scherrer V, Faivre E, Baqi Y, Müller CE, Pimentel J, Schiffmann SN, Buée L, Bader M, Outeiro TF, Blum D, Cunha RA, Marie H, Pousinha PA and Lopes LV (2018) Age-related shift in LTD is dependent on neuronal adenosine A2A receptors interplay with mGluR5 and NMDA receptors. Molecular Psychiatry (in press). doi: 10.1038/s41380-018-0110-9.
111. Chaalal A, Poirier R, Blum D, Laroche S, Enderlin V (2018) Thyroid hormone supplementation restores spatial memory, hippocampal markers of neuroinflammation, plasticity-related signalling molecules and β-amyloid peptide load in hypothyroid rats. Mol Neurobiol (in press). doi: 10.1007/s12035-018-1111-z.
110. Blum D, Chern Y, Domenici MR, Buee L, Lin CY, Rea W, Ferre S & Popoli P (2018) The role of adenosine tone and adenosine receptors in Huntington Disease. Journal of Caffeine and Adenosine Research 8(2):43-58.
109. Lee CC, Chang CP, Lin CJ, Lai HL, Kao YH, Cheng SJ, Chen HM, Liao YP, Faivre E, Buée L, Blum D, Fang JM, Chern Y. Adenosine Augmentation Evoked by an ENT1 (2018) Inhibitor Improves Memory Impairment and Neuronal Plasticity in the APP/PS1 Mouse Model of Alzheimer's Disease. Mol Neurobiol 55(12):8936-8952.
108. Popelová A, Pražienková V, Neprašová B, Kasperová BJ, Hrubá L, Holubová M, Zemenová J, Blum D, Železná B, Galas MC, Kuneš J, Maletínská L. Novel Lipidized Analog of Prolactin-Releasing Peptide Improves Memory Impairment and Attenuates Hyperphosphorylation of Tau Protein in a Mouse Model of Tauopathy. J Alzheimers Dis. 62(4):1725-1736.
107. Gratuze M*, Joly-Amado A*, Vieau D, Buée L, Blum D (2018) Mutual relationship between Tau and central insulin signalling: consequences for AD and Tauopathies ? Neuroendocrinology (in press). DB corresponding author
106. Laurent C, Buée L & Blum D (2018) Tau and neuroinflammation: what impact for AD and Tauopathies ? Biomedical Journal 41(1):21-33. DB corresponding author
105: Vandenbussche C, Van der Hauwaert C, Dewaeles E, Franczak J, Hennino MF, Gnemmi V, Savary G, Tavernier Q, Nottet N, Paquet A, Perrais M, Blum D, Mari B, Pottier N, Glowacki F, Cauffiez C. Tacrolimus-induced nephrotoxicity in mice is associated with microRNA deregulation. Arch Toxicol. 92(4):1539-1550.
104: Vercruysse P, Vieau D, Blum D, Petersén Å, Dupuis L. Hypothalamic Alterations in Neurodegenerative Diseases and Their Relation to Abnormal Energy Metabolism. Front Mol Neurosci. 2018 Jan 19;11:2. doi: 10.3389/fnmol.2018.00002.
103. Sotiropoulos I, Galas MC, Silva JM, Skoulakis E, Wegmann S, Maina MB, Blum D, Sayas CL, Mandelkow EM, Mandelkow E, Spillantini MG, Sousa N, Avila J, Medina M, Mudher A & Buee L (2017). Atypical, non-standard functions of the microtubule associated Tau protein . Acta Neuropathologica Communications 29;5(1):91
102. Laurent C, Dorothée G, Hunot S, Martin E, Delarasse C, Buée L, Blum D. Tau and cognitive disorders: a role for T lymphocytes. Med Sci (Paris). 2017 Oct;33(10):817-819.
101. Duroux R, Renault N, Cuelho JE, Agouridas L, Blum D, Lopes LV, Melnyk P, Yous S. Design, synthesis and evaluation of 2-aryl benzoxazoles as promising hit for the A(2A) receptor. J Enzyme Inhib Med Chem. 2017 Dec;32(1):850-864.
100. Marciniak E, Leboucher A, Caron E, Ahmed T, Tailleux A, Dumont J, Issad T, Gerhardt E, Pagesy P, Vileno M, Bournonville C, Hamdane M, Bantubungi K, Lancel S, Demeyer D, Eddarkaoui S, Vallez A, Vieau D, Humez S, Faivre E, Grenier-Boley B, Outeiro TH, Staels B, Amouyel P, Balschun D, Buee L* & Blum D*. Tau deletion promotes brain insulin resistance (2017) The Journal of Experimental Medicine 214(8):2257-2269. DB corresponding author
99. Adenosine Receptors in Neurodegenerative Diseases. Edited by Luisa V. Lopes and David Blum. Elsevier 2017
98. Gibier JB, Hémon B, Fanchon M, Gaudelot K, Pottier N, Ringot B, Van Seuningen I, Glowacki F, Cauffiez C, Blum D, Copin MC, Perrais M, Gnemmi V (2017) Dual MUC1 functions during kidney ischemia-reperfusion. BBA - Molecular Basis of Disease (in press).
97. Laurent C, Dorothée G, Hunot S, Martin E, Monnet Y, Duchamp M, Dong Y, Legeron FP, Leboucher A, Burnouf S, Faivre E, Carvalho K, Caillierez R, Zommer N, Demeyer D, Jouy N, Sazdovitch V, Schraen-Maschke S, Delarasse C, Buée L* & Blum D* (2016) Hippocampal T cell infiltration promotes neuroinflammation and cognitive decline in a mouse model of Tauopathy. Brain 140(Pt 1):184-200. DB corresponding author
96. Laurent C*, Burnouf S*, Ferry B, Batalha V, Coehlo J, Baqi Y, Malik E, Marciniak E, Parrot S, Van der Jeugd A, Faivre E, Flaten V, Ledent C, d’Hooge R, Sergeant N, Hamdane M, Humez S, Müller CE, Lopes LV, Buée L & Blum D (2016) A2A adenosine receptor deletion is protective in a mouse model of Tauopathy. Molecular Psychiatry 21(1):97-107. doi: 10.1038/mp.2015.115. DB corresponding author
95. Paban V, Loiod B, Villard C, Buée L, Blum D, Pietropaolo S, Cho YH, Andrieux A & Alesco-Lautier B (2017) Omics analysis of mice brain modeling human diseases. Gene 600:90-100.
94. Batalha VL, Ferreira D, Coelho JE, Valadas J, Gomes R, Temido-Ferreiera M, Schmidt T, Baqi Y, Buée L, Müller CE, Hamdane M, Outeiro TF, Bader M, Meijsing SH, Sadri-Vakili G, Blum D* & Lopes LV* (2016) The caffeine-binding adenosine A2A receptor induces age-like HPA-axis dysfunction by targeting glucocorticoid receptor function. Scientific reports 6:31493. doi: 10.1038/srep31493 * senior corresponding authors
93. Chen W, Abud EA, Yeng ST, Lakatos A, Nassi T, Wang J, Blum D, Buée L, Poon WW & Blurton-Jones M (2016) Increased tau pathology promotes the microglial phagocytosis of Aβ. Acta Neuropathologica Communications 4(1):63. doi: 10.1186/s40478-016-0336-1.
92. Beatriz E. García-Gómez BE, , Fernández-Gómez FJ, E Muñoz-Delgado E, Buée L, Blum D & Vidal CJ (2016) Hippocampal Expression of ACh-Related Enzymes in the THY-Tau22 Mouse, a Model of Tauopathy. J Mol Neuroscience 58(4):411-5.
91. Blum D, Herrera F, Francelle L, Mendes T, Basquin M, Obriot H, Demeyer D, Sergeant N, Gerhardt E, Brouillet E, Buée L & Outeiro TF (2015) Mutant huntingtin alters Tau phosphorylation and subcellular distribution. Human Molecular Genetics 24(1):76-85. DB corresponding author.
90. Derisbourg M, Leghay C, Chiappetta G, Fernandez-Gomez FJ , Laurent C , Demeyer D, Carrier S, Buée-Scherrer V, Blum D, Vinh J, Sergeant N, Verdier Y, Buée L & Hamdane M (2014) Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms. Scientific reports 5:9659. doi:10.1038/srep09659.
89. Burlot MA, Brodeau J, Michaelsen K, Potier B, Ayciriex S, Varin J, Gautier B, Djelto F, Audrain M, Dauphinot L, Fernandez-Gomez F, Caillierez R, Olivier Laprevote, Bièche I, Auzeil N, Potier MC, Dutar P, Korte M, Buée L, Blum D, Cartier N (2015) Cholesterol 24-hydroxylase defect is implicated in memory and synaptic impairments associated with Tauopathy in THY-Tau22 mouse model. Human Molecular Genetics 24(21):5965-76.
88. Delaby C, Gabelle A, Blum D, Schraen-Maschke S, Moulinier, A, Boulangien J, Severac D, Buée L, Reme T & Lehmann S (2015). Central and peripheral inflammatory processes in Alzheimer’s disease: biomarker profiling approach. Frontiers in Neurology 24;6:181. doi: 10.3389/fneur.2015.00181.
87. Marciniak E, Faivre E, Dutar P, Alves-Pires C, Demeyer D, Caillierez R, Laloux C, Buée L, Blum D* & Humez S* (2015) The Chemokine MIP-1α/CCL3 impairs mouse hippocampal synaptic transmission, plasticity and memory. Scientific Reports 5:15862. doi: 10.1038/srep15862.DB corresponding and *senior author
86. Moas-Heloire V, Renault N, Batalha V, Rincon A, Marchivie M, Yous Ss Deguine N, Buée L, Chavatte P, Blum D, Lopes LV, Melnyk P, Agouridas L (2015) Design and synthesis of fused tetrahydroisoquinoline-iminoimidazolines. Eur J Med Chem 106:15-25.
85. Blum D, Sandau U, Bousiges O, Lopes LV, Flaten V, Faivre E, Buée L, Boutillier AL & Boison D (2014) Adenosine and Alzheimer's disease, a possible epigenetic link. In Homeostatic Control of Brain Function. Masino & Boison Eds. Oxford University Press. DB corresponding author
84. Martel G, Simon A, Nocera S, Kalainathan S, Pidoux L, Blum D, Leclère-Thurbant S, Diaz J, Geny D, Moyse E, Videau C, Buée L, Epelbaum J, Viollet C. Aging, but not Tau pathology, impacts olfactory performances and somatostatin systems in mice. Neurobiology of Aging (in press).
83. Ahmed T, Blum D, Burnouf S, Demeyer D, Buée-Scherrer V, D’Hooge R, Buée L & Balschun D (2014) Inhibition of GSK3β and activation of PP2A rescue defects in NMDAR-mediated late phase LTD in a Tau transgenic mouse model. Neurobiology of Aging (in press).
82. Blum D, Herrera F, Francelle L, Mendes T, Basquin M, Obriot H, Demeyer D, Sergeant N, Gerhardt E, Brouillet E, Buée L & Outeiro TF (2014) Mutant huntingtin alters Tau phosphorylation and subcellular distribution. Human Molecular Genetics (in press). DB corresponding author
81. Chaalal A, Poirier R, Blum D, Gillet B, Le Blanc P, Basquin M, Buée L, Laroche S & Enderlin V (2014) Hypothyroidism induces Alzheimer’s disease-related pathological hallmarks and associated memory impairments. Hippocampus (in press). doi: 10.1002/hipo.22319
80. Jerónimo-Santos A, Henriques Vaz S, Parreira S, Lérias S, Caetano AP, Buée-Scherrer V, Castren E, Valente CA, Blum D, Sebastiao AM & Diogenes MJ (2014) Dysregulation of TrkB receptors and BDNF function by amyloid-β peptide is mediated by calpain. Cerebral Cortex (in press/ pii: bhu105).
79. Ahmed T, Van der Jeugd A, Blum D, Galas MC, Balschun D, Buée L, & d’Hooge R (2014) Behavioural and hippocampal synaptic plasticity in an homozygous tau deletion. Neurobiology of Aging (in press). doi: 10.1016/j.neurobiolaging.2014.05.005.
78. Laurent C, Eddarkaoui S, Derisbourg M, Leboucher A, Demeyer D, Carrier S, Schneider M, Hamdane M, Müller CE, Buée L & Blum D (2014) Benefical effects of caffeine in a transgenic model of Alzheimer’s disease –like Tau pathology (in press). doi: 10.1016/j.neurobiolaging.2014.03.027. DB corresponding author
77. Flaten V*, Laurent C*, Coelho JE, Sandau U, Batalha VL, Burnouf S, Hamdane M, Humez S, Boison D, Lopes LV, Buée L & Blum D (2013) From epidemiology to pathophysiology: what about caffeine in Alzheimer’s disease ? Biochemical Society Transactions 42(2):587-92. DB corresponding author
76. Fernandez-Gomez FJ, Jumeau F, Derisbourg M, Burnouf S, Tran H, Eddarkaoui S, Obriot H, Dutoit-Lefevre V, Deramecourt V, Mitchell V, Lefranc D, Hamdane M, Blum D, Buee L, Buée-Scherrer V & Sergeant N (2014) Consensus brain-derived protein, extraction protocol for the study of human and murine brain proteome using both 2D-DIGE and mini 2DE immunoblotting. J Vis Exp. 10;(86).
75. Van der Jeugd A, Vermarcke B, Derisbourg M, Hamdane M, Blum D, Buee L & D’Hooge R (2013) Progressive age-related cognitive decline in Tau mice. Journal of Alzheimer Disease 37(4):777-88.
74. Simonin C, Duru C, Salleron J, Hincker P, Charles P, Delval A, Youssov K, Burnouf S, Azulay JP, Verny C, Tranchant C, Goizet C, Defebvre L, Sablonnière B, Rousseau M, Buée L, Destée A, Godefroy O, Dürr A, Landwehrmeyer B, Bachoud-Levi AC, Richard F*, Blum D* & Krystkowiak P* (2013) Association between caffeine intake and age at onset in Huntington's disease. Neurobiology of Disease 58:179-182. DB corresponding author
73. Lo A, Iscru E, Blum D, Tesseur I, Callaerts-Vegh Z, Buee L, De Strooper B, Balschun D & D’Hooge R (2013) Amyloid and tau neuropathology differentially affect prefrontal synaptic plasticity and cognitive performance in mouse models of Alzheimer’s disease. Journal of Alzheimer Disease 37:109-25.
72. Blum D & Buée L (2013) Alzheimer’s Disease risk, Obesity and Tau: is insulin resistance guilty? Expert Review of Neurotherapeutics 13(5):461-3. (invited editorial). DB corresponding author
71. Van der Jeugd A, Blum D, Raison S, Buée L & D’Hooge R (2013) Observations in THY-Tau22 mice that resemble behavioural and psychological signs and symptoms of dementia. Behavioural Brain Research 242:34-9.
70. Leboucher A, Laurent C, Fernandez-Gomes F, Burnouf S, Troquier L, Eddarkaoui S, Brion I, Vallez E, Demeyer D, Caillierez R, Zommer N, Bantubungi K, Lestavel S, Breton C, Staels B, Pigny P, Hamdane M, Muhr-Tailleux A, Buée L & Blum D (2013) Detrimental effects of Diet-induced obesity on Tau pathology is independent of insulin resistance in Tau transgenic mice. Diabetes 62(5):1681-8. DB corresponding author
69. Burnouf S, Martire A, Derisbourg M, Laurent C, Belarbi K, Leboucher A, Fernandez-Gomez F, Troquier L, Eddarkaoui S, Grosjean ME, Demeyer D, Muhr-Tailleux A, Buisson A, Sergeant N, Hamdane M, Humez S, Popoli P, Buée L & Blum D (2013) NMDA receptor dysfunction contributes to impaired BDNF-induced facilitation of hippocampal synaptic transmission in a Tau transgenic model Aging Cell 12(1):11-23. DB corresponding author
68. Moreau C, Delval A, Tiffreau V, Defevbre L, Dujardin K, Duhamel A, Petyt G, Hosseil-Foucher C, Blum D, Sablonniere B, Schaen-Maschke S, Allorge D, Destee A, Bordet R & Devos D (2013) Memantine for axial signs in Parkinson's disease: a randomized, double-blind, placebo-controlled pilot study. Journal of Neurology, Neurosurgery & Psychiatry 84(5):552-5.
67. Ando K, Dourlen P, Sambo AV, Bretteville A, Belarbi K, Vingtdeux V, Eddarkaoui S, Drobecq H, Ghestem A, Bégard S, Demey-Thomas E, Melnyk P, Smet C, Lippens G, Maurage CA, Caillet-Boudin ML, Verdier Y, Vingh J, Landrieu I, Galas MC, Blum D, Hamdane M, Sergeant N & Buée L (2012) Tau pathology modulates Pin1 post-translational modifications and may be relevant as biomarker. Neurobiology of Aging 34(3):757-69.
66. Rosenmann H, Blum D, Kayed R & LM Ittner (2012) Tau protein : function and pathology (Editorial as Guest Editor). International Journal of Alzheimer’s Disease 2012:707482.
65. Brouillette J, Caillierez R, Zommer N, Alves-Pires C, Benilova I, Blum D, De Strooper B, Buée L (2012) Neurotoxicity and Memory Deficits Induced by Soluble Low-Molecular-Weight Amyloid-β1-42 Oligomers Are Revealed In Vivo by Using a Novel Animal Model. The Journal of Neuroscience. 32(23):7852-61.
64. Le Freche H, Brouillette J, Fernandez-Gomez FJ, Patin P, Caillierez R, Zommer N, Sergeant N, Buée-Scherrer V, Lebuffe G, Blum D, Buée L (2012) Tau Phosphorylation and Sevoflurane Anesthesia: An Association to Postoperative Cognitive Impairment. Anesthesiology 116(4):779-87.
63. Blum D, Martire A, Burnouf S, Sablonnière B, Krystkowiak P, Ledent C, Lopes LV & Popoli P (2011) Adenosine receptors in Huntington’s disease. Invited review to be published in Adenosine: a Key Link between Metabolism and CNS Activity. Masino & Boison Eds. Springer. DB corresponding author
62. Blum D, Sandau U, Laurent C, Vania Batalha, Leboucher A, Hamdane M, Pasquier F, Boison D, Buee L & Lopes L (2011) Adenosine receptors in Alzheimer’s disease. Invited review to be published in Adenosine: a Key Link between Metabolism and CNS Activity. Masino & Boison Eds. Springer. DB corresponding author
61. Burnouf S, Belarbi K, Troquier L, Derisbourg M, Demeyer D, Leboucher A, Laurent C, Hamdane M, Buée L & Blum D (2011) Hippocampal BDNF expression in a Tau transgenic mouse model. Current Alzheimer Research 9(4):406-10.
60. Troquier L, Caillierez R, Burnouf S, Fernandez-Gomez FJ, Grosjean ME, Zommer N, Sergeant N, Schraen-Maschke S, Blum D & Buée L (2011) Targeting phospho-Ser422 by active Tau immnotherapy in the THY-Tau22 mouse model : a suitable therapeutic approach. Current Alzheimer Research 9(4):397-405.
59. Burnouf T, Kuo YP, Blum D, Burnouf S & Su CY (2011) Human platelet concentrates: a source of solvent-detergent treated highly-enriched brain-derived neurotrophic factor (BDNF). Transfusion. doi: 10.1111/j.1537-2995.2011.03494.x.
58. Lim S, Chesser AS, Grima JC, Rappold PM, Blum D, Przedborski S, Tieu K. D-β-Hydroxybutyrate Is Protective in Mouse Models of Huntington's Disease. PLoS One. 2011;6(9):e24620.
57. Belarbi K*, Burnouf S*, Laurent C, Fernandez-Gomez FJ, Lestavel S, Figeac M, Sultant A, Troquier L, Leboucher A, Caillierez R, Grosjean ME, Demeyer D, Obriot H, Brion I, Barbot B, Galas MC, Staels B, Humez S, Sergeant N, Schraen-Maschke S, Muhr-Tailleux A, Hamdane M, Buée L & Blum D (2011) Effects of long-lasting physical activity in a transgenic mouse model of Alzheimer’s disease-like Tau pathology. Neurobiology of Disease 43:486-94. DB corresponding author.
56. Mievis S, Blum D* & Ledent C* (2011) Worsening of Huntington disease phenotype in CB1 receptor knockout mice. Neurobiology of Disease 42:524-529. *equal contribution. DB corresponding author.
55. Van der Jeugd A, Ahmed T, Burnouf S, Belarbi K, Hamdame M, Grosjean ME, Humez S, Balschun D, Blum D, Buee L, & D'Hooge R (2011) Hippocampal tauopathy in tau transgenic mice coincides with impaired hippocampus-dependent learning and memory, and attenuated late-phase long-term depression of synaptic transmission. Neurobiology of Learning and Memory 95:296-304.
54. Belarbi K*, Burnouf S*, Fernandez-Gomez FJ, Demercieres J, Troquier L, Brouillette J, Tsambou L, Grosjean ME, Caillierez R, Demeyer D, Hamdane M, Schindowski K, Blum D & Buée L (2011) Loss of medial septum cholinergic neurons in THY-Tau22 mouse model: what link with tau pathology? Current Alzheimer Research 8(6):633-8. *equal contribution
53. Mievis S, Blum D* & Ledent C* (2011) Adenosine A2A receptor knockout worsens survival and motor behaviour in a transgenic mouse model of Huntington's disease. Neurobiology of Disease 41:570-576. *equal contribution. DB corresponding author.
52. Buée L, Blum D, Bombois S, Buée-Scherrer V, Caillet-Boudin ML, Colin M, Deramecourt V, Dhaenens CM, Galas MC, Hamdane M, Humez S, Maurage CA, Pasquier F, Sablonnière B, Schraen-Maschke S, Sergeant N (2010) Molecular Actors in Alzheimer's Disease: Which Diagnostic and Therapeutic Consequences ? Therapie 65:401-407.
51. Buée L, Troquier L, Burnouf S, Belarbi K, Van der Jeugd A, Ahmed T, Fernandez-Gomez F, Caillierez R, Grosjean ME, Begard S, Barbot B, Demeyer D, Obriot H, Brion I, Balschun D, D’Hooge R, Hamdane M, Blum D, Sergeant N (2010) From Tau phosphorylation to Tau aggregation: what about neuronal death ? Biochemical Society Transactions 38:967-72.
50. Feuillete S, Deramecourt V, Laquerriere A, Duyckaerts C, Delisle MB, Maurage CA, Blum D, Buée L, Frebourg T, Campion D & Lecourtois M (2010) Filamin-A and myosin VI colocalize with fibrillary Tau protein in Alzheimer's disease and FTDP-17 brains Brain Research 1345:182-9.
49. El-Ekiaby M, Sayed MA, Caron C, Burnouf S, El-Sharkawy N, Goubran H, Radosevich M, Goudemand J, Blum D, de Melo L, Soulié V, Adam J & Burnouf T (2010) Solvent-detergent filtered (S/D-F) fresh frozen plasma and cryoprecipitate minipools prepared in a newly designed integral disposable processing bag system. Transfusion Medicine 20:48-61.
48. Dhanens CM*, Burnouf S*, Simonin C, Vanbrussel E, Duhamel A, Defebvre L, Duru C, Vuillaume I, Cazeneuve C, Charles P, Maison P, Debruxelles S, Verny C, Gervais H, Azulay JP, Tranchant C, Bachoud-Levi AC, Dürr A, Buée L, Krystkowiak P*, Sablonnière B* & Blum D* (2009) A genetic variation in the ADORA2A gene modifies age at onset in Huntington's disease. Neurobiology of Disease 35:374-376. *equal contribution.
47. Belarbi K, Schindowski K, Burnouf S, Caillerez R, Grosjean ME, Demeyer D, Hamdane M, Sergeant N, Blum D & Buee L (2009) Early Tau pathology involving the septo-hippocampal pathway in a Tau transgenic model : relevance to Alzheimer’s disease. Current Alzheimer Research 6:152-157.
46. Caparros D, Kerdraon O, Maurage CA, Blum D, Delacourte A & Sablonniere B (2009) Huntington's Disease : can tau aggregates protect huntingtin toxicity ? Movement Disorders 24:1089-1090.
45. Sergeant N, Bretteville A, Hamdane M, Caillet-Boudin ML, Grognet P, Bombois S, Blum D, Delacourte A, Pasquier F, Van Mechelen E, Schraen-Maschke S & Buee L (2008) Biochemistry of Tau in Alzheimer's Disease and related disorders. Expert Review in Proteomics 5:207-24.
44. Popoli P*, Blum D*, Dominici MR, Burnouf S & Chern Y* (2008) A critical evaluation of adenosine A2A receptors as potentially "druggable" targets in Huntington's disease. Current Pharmaceutical Design 14:1500-11. *equal contribution
43. Bantubungi K*, Blum D*, Cuvelier L, Wislet S, Rogister B, Brouillet E & Schiffmann SN (2008) Stem Cell Factor and stem cell transplantation in a model of Huntington's disease. Molecular and Cellular Neuroscience 35:454-70. *equal contribution
42. Lubansu A, Abeloos L, Blum D, Brotchi J, Leviver M & Tenenbaum L (2007) Recombinant AAV viral vectors serotype 1, 2 and 5 mediate differential gene transfer efficiency in rat striatal fetal grafts. Cell transplantation 16:1013-20.
41. Bantubungi K & Blum D (2007) Molecular mechanisms of neuronal death in Huntington's disease. Revue Médicale de Bruxelles. First part: general considerations and histopathological features 28:413-21. DB corresponding author.
40. Bantubungi K & Blum D (2007) Molecular mechanisms of neuronal death in Huntington's disease. Revue Médicale de Bruxelles. Second part: therapeutic challenges 28:487-94. DB corresponding author.
39. Minghetti L, Greco A, Potenza RL, Pezzola A, Blum D, Bantubungi K & Popoli P (2007) Effects of the adenosine A2A receptor antagonist SCH 58261 on cyclooxygenase-2 expression, glial activation and BDNF avaibility in a rat model of striatal neurodegeneration. Journal of Neuropathology and Experimental Neurology 66:363-71.
38. Stathopoulos A, Melas C, Attali B, Blum D, Leviver M, Brotchi J, Velu T & Tenenbaum L (2007) Overexpression of mouse IsK protein fused to green fluorescent protein induces apoptosis of human astroglioma cells. Neurological Research Res 29:628-31.
37. Chtarto A, Yang X, , Bockstael O, Melas C, Blum D, Lehtonen E, Abeloos L, Jaspar JM, Levivier M, Brotchi J, Velu T & Tenenbaum L (2007) Controlled delivery of glial cell line-derived neurotrophic factor by a single-inducible AAV vector. Experimental Neurology 204:387-399.
36. Popoli P*, Blum D*, Martire A, Ledent C, Ceruto S & Abbracchio MP* (2007) Functions, dysfunctions and therapeutic potential of adenosine A2A receptors in Huntington’s disease. Progress in Neurobiology 81:331-48. *equal contribution
35. Mievis S, Levivier M, Vassart G, Brotchi J, Ledent C* & Blum D* (2007) Citicoline is not protective in experimental models of Huntington’s Disease. Neurobiology of Aging 28:1944-46. *equal contribution. DB corresponding author.
34. Mievis S, Levivier M, Communi D, Vassart G, Brotchi J, Ledent C* & Blum D* (2007) Lack of minocycline efficiency in genetic models of Huntington’s disease. Neuromolecular Medicine 9:47-54. *equal contribution. DB corresponding author.
33. Galas MC, Dourlen P, Bégard S, Ando K, Blum D, Hamdane M & Buée L (2006) The peptidyl prolyl cis/trans isomerase Pin1 modulates stress-induced dephosphorylation of Tau in neurons: implication in a pathological mechanism related to Alzheimer’s disease. The Journal of Biological Chemistry 281:19296-19304.
32. Brouillet E, Jacquard C, Bizat N & Blum D (2005) 3-nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington’s disease. The Journal of Neurochemistry 95:1521-40.
31. Bizat N, Galas MC, Jacquard C, Boyer F, Schiffmann SN, Hantraye P, Blum D & Brouillet, E. (2005) Neuroprotective effects of zVAD-fmk against 3-nitropropionic acid involves direct inhibition of calpain. Neuropharmacology 49:695-702.
30. Ledent C, Demeestere I, Blum D, Petermans J, Hämäläinen T, Guillaume S & Vassart G (2005) Premature ovarian aging in mice deficient for Gpr3. PNAS 102: 8922-8926.
29. Guntz E, Dumont H, Roussel C, Gall D, Dufrasne F, Cuvelier L, Blum D, Schiffmann SN & Sosnowski M (2005) Effects of Remifentanil on N-methyl-D-aspartate Receptor: An Electrophysiological Study in Rat Spinal Cord. Anesthesiology 102:1235-1241.
28. Ceballos-Picot, I., Blum, D., Ramassamy, C. & Przedborski, S. (2005) Le stress oxydant dans les processus neurodégénératifs et la mort neuronale : cause ou conséquence ? In Radicaux libres et stress oxydant : Aspects biologiques et pathologiques. Editions Lavoisier/Tec&Doc pp 429-460.
27. Bantubungi K, Jacquard C, Greco A, Pintor A, Chtarto A, Tai K, Galas MC, Tenenbaum L, Deglon N, Popoli P, Minghetti L, Brouillet E, Brotchi J, Levivier M, Schiffmann SN & Blum D (2005) Minocycline in phenotypic models of Huntington's disease. Neurobiology of Disease 18: 206-217. DB corresponding author.
26. Blum D, Chtarto A, Tenenbaum L, Brotchi J & Levivier M (2004) Clinical potential of minocycline for neurodegenerative disorders. Neurobiology of Disease 17: 359-366. DB corresponding author.
25. Galas MC, Bizat N, Cuvelier L, Bantubungi K, Brouillet E, Schiffmann SN & Blum D (2004) Death of cortical and striatal neurons induced by mitochondrial defect involves differential molecular mechanisms. Neurobiology of Disease 15: 152-159. DB corresponding author.
24. Blum D (2004) Les modèles animaux de la maladie de Huntington. In Huntington : maladie et problématique. Manuel à l’intention des professionnels de langue française. Edité par la Ligue Huntington Francophone Belge. 67-74.
23. Blum D, Galas MC, Cuvelier L & Schiffmann SN (2004) Chronic intoxication with 3-nitropropionic acid in rats induces the loss of striatal dopamine terminals without affecting nigral cell viability. Neuroscience Letters 354: 234-238. DB corresponding author.
22. Blum D, Hemming FJ, Galas MC, Torch S, Cuvelier L, Schiffmann SN & Sadoul R (2004) Increased Alix (apoptosis-linked gene-2 interacting protein X) immunoreactivity in the degenerating striatum of rats chronically treated by 3-nitropropionic acid. Neuroscience Letters 368: 309-313. DB corresponding author.
21. Popoli P, Blum D, Pintor A, Tebano MT, Frank C, Gianfriddo M, Domenici MR, Schiffmann SN & Pedata F (2004) The controversial role of adenosine A2A receptor antagonists as neuroprotective agents. Current Medicinal Chemisty-CNS Agents 4: 35-45.
20. Chtarto A, Tenenbaum L, Velu T, Brotchi J, Levivier M & Blum D (2003) Minocycline-induced activation of tetracycline-responsive promoter. Neuroscience Letters 352: 155-158. DB corresponding author.
19. Gall D, Roussel C, Susa I, D'Angelo E, Rossi P, Bearzatto B, Galas MC, Blum D, Schurmans S & Schiffmann SN (2003) Altered neuronal excitability in cerebellar granule cells of mice lacking calretinin. The Journal of Neuroscience 23: 9320-9327.
18. Blum D, Hourez R, Galas MC, Popoli P & Schiffmann SN (2003) Adenosine receptors and Huntington's disease: implications for pathogenesis and therapeutics. The Lancet Neurology 2: 366-374. DB corresponding author.
17. Blum D, Galas MC, Pintor A, Brouillet E, Ledent C, Muller CE, Bantubungi K, Galluzzo M, Gall D, Cuvelier L, Rolland AS, Popoli P & Schiffmann SN (2003) A dual role of adenosine A2A receptors in 3-nitropropionic acid-induced striatal lesions: implications for the neuroprotective potential of A2A antagonists. The Journal of Neuroscience 23: 5361-5369. DB corresponding author.
16. Tenenbaum L, Chtarto A, Lehtonen E, Blum D, Baekelandt V, Velu T, Brotchi J & Levivier M (2002) Neuroprotective gene therapy for Parkinson's disease. Current Gene Therapy 2: 451-483.
15. Ponzoni S, Gaziri LC, Britto LR, Barreto WJ & Blum D (2002) Clearance of manganese from the rat substantia nigra following intra-nigral microinjections. Neuroscience Letters 328: 170-174. DB corresponding author.
14. Blum D, Gall D, Galas MC, D'Alcantara P, Bantubungi K & Schiffmann SN (2002) The adenosine A1 receptor agonist adenosine amine congener exerts a neuroprotective effect against the development of striatal lesions and motor impairments in the 3-nitropropionic acid model of neurotoxicity. The Journal of Neuroscience 22: 9122-9133. DB corresponding author.
13. Blum D, Galas MC, Gall D, Cuvelier L & Schiffmann SN (2002) Striatal and cortical neurochemical changes induced by chronic metabolic compromise in the 3-nitropropionic model of Huntington's disease. Neurobiology of Disease 10: 410-426. DB corresponding author.
12. Blum D, Gall D, Cuvelier L & Schiffmann SN (2001) Topological analysis of striatal lesions induced by 3-nitropropionic acid in the Lewis rat. Neuroreport 12: 1769-1772. DB corresponding author.
11. Lambeng N, Hourez R, Torch S, Verna JM & Blum D (2002) Biochemical and molecular mechanisms of neuronal cell death in the experimental neurotoxic models of Parkinson's disease. Medecine Sciences 18: 457-466. DB corresponding author.
10. Blum D, Torch S, Lambeng N, Nissou M, Benabid AL, Sadoul R & Verna JM (2001) Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Progress in Neurobiology 65: 135-172. DB corresponding author.
9. Blum D, Torch S, Nissou MF & Verna JM (2001) 6-hydroxydopamine-induced nuclear factor-kappa B activation in PC12 cells. Biochemical Pharmacology 62: 473-481. DB corresponding author.
8. Seegers H, Grillon E, Trioullier Y, Vath A, Verna JM & Blum D (2000) Nuclear factor-kappa B activation in permanent intraluminal focal cerebral ischemia in the rat. Neuroscience Letters 288: 241-245. DB corresponding author.
7. Blum D, Torch S, Nissou MF, Benabid AL & Verna JM (2000) Extracellular toxicity of 6-hydroxydopamine on PC12 cells. Neuroscience Letters 283: 193-196. DB corresponding author.
6. Blum D, Torch S, Nissou MF & Verna JM (2000) A cautionary note on the use of stable transformed cells. Apoptosis 5: 115-116. DB corresponding author.
5. Bezin L, Marcel D, Garcia C, Blum D, Lafargue P, Lellouche JP, Pujol JF & Weissmann D (2000) In situ examination of tyrosine hydroxylase activity in the rat locus coeruleus using (3',5')-[(3)H(2)]-alpha-fluoromethyl-tyrosine as substrate of the enzyme. Synapse 35: 201-211.
4. Blum D, Vicat JM, Berger F, Benabid AL & Wion D (1999) Mycoplasmas as gene therapy vectors? Nature Biotechnology 17: 4.
3. Vicat JM, Blum D, Wion D, Benabid AL & Berger F (1998) RLU and studies using the luciferase reporter gene. Nature Biotechnology 16: 702.
2. Blum D, Wu Y, Nissou MF, Arnaud S, Alim LB & Verna JM (1997) p53 and Bax activation in 6-hydroxydopamine-induced apoptosis in PC12 cells. Brain Research 751: 139-142.
1. Wu Y, Blum D, Nissou MF, Benabid AL & Verna JM (1996) Unlike MPP+, apoptosis induced by 6-OHDA in PC12 cells is independent of mitochondrial inhibition. Neuroscience Letters 221: 69-71.